Drug Profile
Sirolimus inhaled - OrphAI Therapeutics
Alternative Names: LAM 001; Rapamycin inhaled - OrphAI TherapeuticsLatest Information Update: 04 Oct 2023
Price :
$50
*
At a glance
- Originator LAM Therapeutics
- Developer OrphAI Therapeutics
- Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Bronchiolitis obliterans; Pulmonary arterial hypertension; Pulmonary sarcoidosis
- Discontinued Lymphangioleiomyomatosis
Most Recent Events
- 28 Sep 2023 AI Therapeutics is now called OrphAI Therapeutics
- 18 Aug 2023 AI Therapeutics initiates enrolment in a phase II trial for Bronchiolitis Obliterans (Newly diagnosed) in USA (Inhalation)
- 03 Apr 2023 Phase-II clinical trials in Pulmonary arterial hypertension (Adjunctive treatment) in USA (Inhalation) (NCT05798923)